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Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a disorder characterized by vascular manifes-
tations including mucocutaneous and visceral telangiectasias and arteriovenous malforma-
tions. Herein we present the case of a relatively young patient with HHT with an incidentally 
discovered locally advanced esophageal cancer on endoscopic screening and pathologically 
complete response after neoadjuvant chemoradiation. This case highlights an unusual tumor 
response to chemoradiation in locally advanced esophageal cancer, and the surveillance care 
of HHT patients. © 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder with an autosomal 
dominant inheritance and variable penetrance characterized by structural abnormalities of 
the vasculature, resulting in mucocutaneous telangiectasias and arteriovenous malforma-
tions (AVMs) that may involve various organs including the brain, lungs, and the gastrointes-
tinal (GI) tract [1–4]. Prevalence of HHT as suggested by epidemiological studies ranges from 
Published online: February 18, 2020
Anup Kasi
Department of Medicine
Division of Medical Oncology, Kansas University Medical Center
2650 Shawnee Mission Pkwy, Westwood, KS 66205 (USA)
akasi @ kumc.edu
www.karger.com/cro
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 Interna tional License 
(CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial 
purposes requires written permission.
DOI: 10.1159/000505832
177Case Rep Oncol 2020;13:176–181
Park et al.: Pathologically Complete Response of Esophageal Cancer in HHT
www.karger.com/cro
© 2020 The Author(s). Published by S. Karger AG, BaselDOI: 10.1159/000505832
1:5,000 to 1:8,000 [5–10]. The Curaçao Criteria have been developed to guide the diagnosis 
of HHT. The diagnosis is based on the following clinical findings: spontaneous and recurrent 
epistaxis; multiple mucocutaneous telangiectasia at characteristic sites; visceral manifesta-
tions including GI telangiectasia or pulmonary, cerebral, or hepatic AVMs; and a first-degree 
relative with HHT. Three out of four criteria define “definite,” two out of four “suspected,” and 
one out of four “unlikely.” Although not necessary, genetic testing may confirm the diagnosis 
by identifying pathogenic sequence variants in the genes linked to HHT, namely ENG, ACVRL1, 
or SMAD4 [10, 11].
Locally advanced esophageal cancer patients have the option of undergoing triple therapy 
which includes concurrent neoadjuvant chemoradiation followed by esophageal resection 
[12]. A minority subset of patients undergoing triple therapy may achieve pathologically 
complete response (pCR) with studies indicating a range of 19–30% with a lower rate in 
adenocarcinoma [13–20]. Such patients enjoy favorable prognoses compared to their non-pCR 
achieving counterparts in terms of recurrence-free survival and overall survival [14, 21–23]. 
Therefore, achieving pCR is an important prognostic measure of locally advanced esophageal 
cancer patients who have undergone therapy. Herein, we present a patient with underlying 
HHT who achieves pCR following triple therapy for locally advanced esophageal cancer.
Case Report
This is a 40-year-old male patient with a recently diagnosed HHT who had undergone 
screening endoscopy for surveillance of vascular complications. He notes occasional epistaxis 
and buccal macules but denies nausea, vomiting, dysphagia, and weight loss. His past medical 
and surgical history is unremarkable. He is a 15-pack-year smoker and drinks 588 g of alcohol 
weekly but does not use illicit drugs. Family history is significant for cancer in multiple rela-
tives. His mother suffered from head and neck cancer, his maternal grandmother from colon 
cancer, his maternal grandfather from prostate cancer, and his paternal grandmother from 
leukemia. His physical examination is remarkable for buccal telangiectasias and he has a BMI 
of 32.23. Laboratory studies are remarkable for polycythemia. Upper GI endoscopy shows a 
friable mucosa with contact bleeding of the esophagus and normal stomach. Several duodenal 
ectasias are found and treated with plasma coagulation. Capsule endoscopy is done, which is 
unremarkable. Endoscopic ultrasound shows two periesophageal lymph nodes, 11.6 and 7.2 
mm in diameter (Fig. 1). PET-CT confirmed hypermetabolic primary esophageal tumor but 
the periesophageal lymph nodes were non-hypermetabolic due to small size. No metastatic 
lesions are discovered (Fig. 2). Endoscopic biopsy of the ulcerated mucosa of the esophagus 
confirms moderately differentiated adenocarcinoma in a background of high-grade dysplasia. 
The patient is diagnosed with stage IIB, cT1bN1 esophageal adenocarcinoma and undergoes 
neoadjuvant chemoradiation with carboplatin/Taxol then surgical resection with the IVOR-
Lewis approach. Postoperative pathology confirms pCR. His 1-month, 1-year and 2-year post-
operative surveillance upper GI endoscopies reveal no recurrence.
Discussion
A potential molecular relationship may exist between a genetic variant underlying a specific 
subtype of HHT and esophageal cancer pathogenesis. Namely, HHT subtype 1 is associated with 
pathological variants of ENG which encodes a transformation growth factor beta (TGF-β) super-
family auxiliary receptor [24]. Previous studies have demonstrated downregulation of ENG in 
esophageal squamous cell cancer cell lines and patient tumor specimens [25]. Furthermore, 
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functional in vitro and in vivo studies demonstrate the suppressive effects of ENG on tumor 
invasion and tumorigenicity [26]. Other studies suggest the involvement of TGF-β mediated 
tumor suppression in the pathogenesis of esophageal adenocarcinoma as well [27, 28]. Our 
patient, as part of his previous diagnostic evaluation of HHT, underwent genetic testing, which 
Fig. 2. Staging CT scan of the ab-
domen showing thickening of the 
gastroesophageal junction corre-
sponding to the primary lesion. 
Arrow indicates the neoplastic le-
sion at the gastroesophageal junc-
tion with a diameter of 10.30 mm 
(upper panel). Staging PET scan of 
the abdomen showing hyperme-
tabolism in the corresponding 
primary lesion. The neoplastic le-
sion at the gastroesophageal junc-
tion demonstrates hypermetabo-
lism (lower panel).
Fig. 1. Endoscopic ultrasound 
showing 2 periesophageal/peri-
gastric lymph nodes (11.6 mm, 
7.2 mm).
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revealed a genetic variant in ENG. It is difficult to ascertain if and whether the underlying genetic 
variant was associated with the onset of esophageal cancer in this relatively young patient, 
given that he did have risk factors including male sex, obesity, and cigarette smoking [29–32]. 
However, several epidemiological studies show that HHT1 patients have different specific 
cancer rates and specific cancer mortality outcomes that differ from the non-HHT1 population 
[7, 33, 34]. So far, esophageal cancer has not been named as having a different specific cancer 
rate compared to the healthy population but further studies to evaluate the epidemiological 
relationship between HHT and esophageal cancer may be warranted.
The management of HHT patients involves timely and judicious screening for clinically 
significant AVMs. Although international guidelines have been established to facilitate appro-
priate screening, consensus is still lacking and indications for screening remain unclear in 
several areas. The major visceral vascular abnormalities that are the subject of screening 
include cerebral, pulmonary, GI, and hepatic vascular malformations. Evidence for screening for 
pulmonary AVMs in all patients with possible or confirmed HHT is strong. On the other hand, 
the evidence is weak for cerebral vascular malformations. Screening for GI AVMs is recom-
mended in patients who are suspected of GI bleeding, namely if anemia appears out of proportion 
to blood loss by epistaxis. Similarly, screening for liver AVMs is recommended when the liver 
function test is abnormal or clinical complications arising from liver involvement are suspected 
[35]. Upon HHT diagnosis, our patient underwent pulmonary screening and GI screening when 
laboratory studies discovered iron deficiency anemia out of proportion to epistaxis.
As aforementioned, pCR is a positive prognostic indicator and is achieved in approxi-
mately 19–30% of patients who undergo trimodal therapy with neoadjuvant chemoradiation 
and surgery. Certain clinical factors are associated with lower or higher probability of pCR. 
Among clinical factors associated with lower pCR are older age (>60), poorly differentiated 
histology, presence of signet ring cells, higher T stage, and adenocarcinoma subtype [13]. 
Based on the findings of this study, other than the histological subtype, the patient had none 
of these oncologic factors, which in retrospect indicated a relatively high pretreatment prob-
ability of pCR. Furthermore, the pCR suggests a favorable prognosis for this patient. In fact, 
the patient is without evidence of recurrence at his 2-year follow-up.
The lessons of this case are the following: (1) screening guidelines and indications for 
complications in HHT patients are established but many aspects are controversial; (2) certain 
genetic variants associated with HHT may also be involved in esophageal cancer patho-
genesis; and (3) despite its reputation as an aggressive cancer with poor treatment response, 
locally advanced esophageal cancer can have pCR with surprising frequency.
Conclusion
This case describes the diagnosis of a locally advanced esophageal cancer in a relatively 
young patient with a variant gene suspected to be involved in esophageal cancer patho-
genesis.
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